SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a fresh 52-week high ahead of the anticipated Q3 earnings report is driving attention, with traders focused on BRIUMVIs sales momentum and the possibility of an earnings beat. Buyout and short-squeeze speculation is also prominent, but remains unconfirmed.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and heavy AI infrastructure spending drove debate, as investors weighed weaker-than-expected results and sharply negative free cash flow against accelerating AWS growth and its outlook. Traders were split between concerns that cash burn and rising investment could pressure the stock and dip-buyers who viewed the initial selloff as overdone; shares rebounded substantially from their lows.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL combination drew attention after Phase 2 NEOASIS data at ESMO showed strong pathologic responses in a small dMMR colon cancer cohort, alongside discussion of sarcoma results. Traders called the findings encouraging but debated their significance given the small, early-stage studies and awaited Phase 3 confirmation, while some questioned why the share price weakened despite the data and raised dilution and execution concerns.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas prices slide amid mild-weather forecasts that point to weaker heating demand, with surplus inventories adding pressure. Traders are split between buying the decline ahead of winter and expecting further weakness if warm conditions persist; colder forecasts or storage data are seen as potential catalysts for a shift.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the November 14 FDA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer, with traders weighing the Phase 3 results and recent positive biliary-cancer data against regulatory concerns, including the lack of statistically significant overall-survival results. Bulls see approval potential and broader promise for the drug, while skeptics stress that the decision remains uncertain and could hinge on FDA concerns about the trial population or manufacturing.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broader technology and semiconductor selloff after Intels weak outlook heightened concerns about PC demand and chip-sector growth, with traders also scrutinizing AI spending and elevated valuations ahead of AMDs earnings report. The community is split between expecting sympathy selling to reverse because Intels struggles could benefit AMD, and fearing further pressure if AI expectations reset.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced 2026 outlook and dividend suspension have sparked concern about soft appliance demand and financial strain. Traders debate whether the downturn reflects broader economic pressures or years of management problems, with some calling the selloff an overreaction and others warning of further downside and bankruptcy risk.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,864.894765 in circulation. The last known price of Pyth Network is 0.06503621 USD and is up 3.48 over the last 24 hours. It is currently trading on 450 active market(s) with $50,940,939.77 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Traders are focused on Pyths institutional data-feed adoption, including Nasdaq distribution, and the DAOs revenue-funded PYTH accumulation policy; speculation about a teased Pyth Connect announcement is another catalyst in the discussion. Bullish holders see these developments supporting the RWA and oracle narrative, while skeptics point to weak price action and potential token-unlock selling pressure, and the teased announcements substance remains unknown.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,155,828.93500734 in circulation. The last known price of Hedera is 0.07221819 USD and is up 4.74 over the last 24 hours. It is currently trading on 465 active market(s) with $92,347,671.42 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBARs sharp rally and elevated volume are being linked by traders to IBM-related cloud news and Hederas reported connections to NVIDIAs AI safety platform. Enthusiasm over enterprise and AI use cases is tempered by profit-taking and skepticism that the announcements will translate into meaningful adoption or token demand.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report and narrower production guidance are driving the selloff, with traders criticizing the results as underwhelming and pointing to Cigar Lake operating setbacks. Some see the drop as justified by near-term execution concerns, while others argue rising uranium prices and long-term nuclear demand support the investment thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

STRO Stock Plummets 15% —  What Drove The Selloff?

Equity

H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004 by the company. 


Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.read more...

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after strong financial results and $100M investment.read more...

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist Financial

Truist Financial raised shares of Sutro Biopharma to a "strong-buy" rating in a research report on Monday...

Sutro Biopharma (NASDAQ:STRO) Sets New 1-Year High  - Still a Buy?

Sutro Biopharma (NASDAQ:STRO) Sets New 52-Week High - Still a Buy...

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating

Mizuho upgraded shares of Sutro Biopharma to a "strong-buy" rating in a report on Thursday...

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Neutral Sentiment

<ul class="summary-bullets"><li>In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers.</li><li>A fuller update is planned for the first half of 2027.</li><li>As of June 30, Sutro held $164.3 million in cash and securities, enough to fund operations into at least the second quarter of 2028.</li></ul><p>Shares of Sutro Biopharma (STRO) fell 15% on Wednesday after the company reported second-quarter results and an early look at its lead experimental cancer drug STRO-004.</p><p>H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004. The firm said investors had hoped for a more complete readout or enough patient-level information to judge the strength and staying power of the responses. Wainwright views the reaction as overdone because the data remain early, while the drug already shows clearer safety advantages over approved tissue-factor antibody-drug conjugates. The firm reiterated its ‘Buy’ rating and $50 price target. The price target implies a potential upside of 135% from the stock's closing price on Wednesday.&nbsp;</p><h2 class="st-heading-2">Early Signs Of Activity With Good Tolerability</h2><p>In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers. The drug was generally well tolerated, with dose-limiting side effects appearing only at the highest dose tested and leading to reductions rather than dropouts, the company said.</p><p>The overall rate of patients stopping treatment because of side effects was low at 6%. Enrollment of the first dose groups moved faster than expected, and the company is still refining the best dose.</p><p>A fuller update is planned for the first half of 2027. CEO Jane Chung said the early STRO-004 findings strengthen confidence in the drug’s potential to deliver meaningful benefit and open the door to combinations.</p><h2 class="st-heading-2">Pipeline Progress And Solid Cash Position</h2><p>Beyond STRO-004, Sutro expects to start clinical testing of STRO-006, another antibody-drug conjugate for solid tumors, in the third quarter of 2026. Its wholly owned STRO-227 program remains on track for an investigational new drug application later this year and offers a longer-term growth path for the company’s platform.</p><p>As of June 30, Sutro held $164.3 million in cash and securities, enough to fund operations into at least the second quarter of 2028. Second-quarter revenue was $9.8 million, mainly from its collaboration with Japan's Astellas Pharma, while the net loss was $38.5 million.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around STRO stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume remained at ‘high’ levels.</p><p>A Stocktwits user expressed optimism about the company’s pipeline.</p><p><stembedurl>https://www.stocktwits.com/KY3000/message/661632677</stembedurl></p><p><a href="https://stocktwits.com/symbol/STRO">STRO stock</a> has gained 84% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-in-focus-as-candel-nears-year-end-bla-filing-for-prostate-cancer-drug-eyes-10-16-b-opportunity/cZo8g37RJWo">CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Sutro Biopharma logo is seen displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers.A fuller update is planned for the first 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.10
Prev Close	$9.14
Open	$9.04
Dividend Yield	0.00%
50-Day Moving Average	$15.39
Beta	1.51
Avg. Volume	318,291.81
PE Ratio	-0.52

52-Week High	$43.85
52-Week Low	$7.15
Market Capitalization	$150.89M
EPS (Annual)	-$22.49
Price to Book	-1.46
Revenue Per Employee	$748,058.39

Feed

News

Sentiment

Earnings

Fundamentals

Info

STRO Fundamentals